1. Enbrel (Etanercept)
Companies: Amgen, Takeda, Wyeth
Sales: US$7.66 billion (Euros 5.15 billion) in 2008
Indications: Ankylosing spondylitis, juvenile idiopathic arthritis, plaque psoriasis, rheumatoid arthritis

2. Remicade (Infliximab)
Companies: J&J, Mitsubishi Tanabe, Schering Plough
Sales: US$6.2 billion (Euros 4.17 billion) in 2008
Indications: Adult Crohn's disease, ankylosing spondylitis, paediatric Crohn's disease, plaque psoriasis, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis

3. Rituxan (Rituximab)
Company: Roche
Sales: US$5.5 billion (Euros 3.7 billion) in 2008
Indications: Non-Hodgkin's lymphoma and rheumatoid arthritis

4. Avastin (Bevacizumab)
Company: Roche
Sales: US$3.8 billion (Euros 2.55 billion) in 2008
Indications: Glioblastoma, metastatic breast cancer, metastatic colorectal cancer, metastatic renal cell carcinoma, non-squamous non-small cell lung cancer

5. Herceptin (Trastuzumab)
Company: Roche
Sales: US$4.7 billion (Euros 3.16 billion) in 2008
Indications: Breast cancer

6. Humira (Adalimumab)
Company: Abbott
Sales: US$4.5 billion (Euros 3 billion) in 2008
Indications: ankylosing spondylitis, Crohn's disease, chronic plaque psoriasis, ployarticular juvenile idiopathic arthritis, psoriatic arthritis, rheumatoid arthritis

7. Lovenox (Enoxaparin)
Company: Sanofi-aventis
Sales: US$4 billion (Euros 2.69 billion) in 2008
Indications: DVT blood clots

8. Lantus (Insulin)
Company: Sanofi-aventis
Sales: US$3.6 billion (Euros 2.42 billion) in 2008
Indications: Diabetes

9. Aranesp (Darbepoetin)
Company: Amgen
Sales: US$3.1 billion (Euros 2.09 billion) in 2008
Indications: Anaemia

10. Gardasil
Company: Merck
Sales: US$2.8 billion (Euros 1.88 billion) in 2008
Indications: HPV and cervical cancer prevention

References:
Top 10 Blockbuster Biotech Drugs. FierceBiotech. 2009 Nov 3.